CClinicalTrials.gg
CompletedNCT05293444Updated Dec 5, 2023

Effect of Preoperative Carbohydrate Loading on Post-operative Insulin Resistance After Donor Hepatectomy.

An interventional study of Maltodextrine and overnight fasting in Healthy, sponsored by Institute of Liver and Biliary Sciences, India. Completed at 1 site in India. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-12-05.

Sponsored by Institute of Liver and Biliary Sciences, India · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
70
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

It's a randomized control trial to compare the effect of preoperative carbohydrate loading versus fasting on post operative insulin resistance after donor hepatectomy in terms of donor outcomes. Investigator will analyze the data and elucidate the value of post operative insulin resistance in reducing the occurrence of complications, length of hospital stay and fastening the recovery in donors of Live donor liver transplantation.

Read the detailed description

AIM: Investigator aim to study the effect of preoperative carbohydrate loading on insulin resistance and functional recovery after donor hepatectomy.

(B) Methodology: Present study will be a Randomized Control Trial with randomization into either study group or control group. Study group will undergo preoperative carbohydrate loading while control group will have conventional preoperative fasting (minimum 6 hours) in donors undergoing donor hepatectomy in live donor liver transplantation. Patients will be allocated to each arm on the basis of block randomization.

400 ml of clear carbohydrate drink (12.5 g/100 ml maltodextrin,50 kcal/100 ml) at 10 PM night before surgery \& 200 ml, 2 hr before induction of anaesthesia will be given to the study group while overnight fasting(minimum 6 hrs) will be given for control group.

After donor hepatectomy, Insulin resistance will be calculated by HOMA-IR score at 6 AM on Day of Surgery, 6hrs after surgery, 12 hours and 36 hours (POD 2) after surgery. C-reactive protein and IL-6 at 6 AM on Day of Surgery, 48 hrs \& on day 7 after surgery. Functional recovery of remnant liver will be assesed by normalization of total bilirubin and PT/INR till discharge and on day 14 after surgery. Peak lactate levels \& time taken for normalization of lactate will be taken. Incidence of post operative nausea and vomiting and length of hospital stay will be compared between the two groups

Clinical and demographic parameters to be assessed- Donor-preoperative-Age, sex, BMI, LFTs, HbA1c, HOMA-IR, IL-6, CRP Operative parameters-duration of surgery, blood loss Postoperative serial measurements of the following parameters-

HOMA-IR, IL-6, CRP, Lactate level, LFTs, PT-INR, Post operative nausea \& vomiting, Day of discharge These patients would be followed closely in the post-operative period and would be serially sampled at pre-defined time points for the aforementioned variables. At the end of the study the incidence of complications as well as improvement in postoperative recovery will be compared between the 2 groups. The clinical and laboratory parameters will be compared between those received preoperative carbohydrate loading and overnight fasting group.

Study Population: Consecutive patients undergoing live donor hepatectomy at ILBS during the study period.

Study Design:-Randomised Controlled Trial Study Period: December 2021 to May 2023. Inclusion Criteria All consecutive live liver donors who undergo donor hepatectomy at ILBS Exclusion criteria Patients refusing to consent for inclusion in the study. Donor hepatectomy for ALF(acute liver failure) recipient

Sample Size Assuming that HOMA-IR in conventional group is 1.7±0.1 and further investigator assume that there will be 25% reduction by preoperative carbohydrate loading with α-5%, Power- 90% and 1:1 ratio. Investigator need to enroll 70 cases i.e, 35 in each group. They will be randomly allocated in two groups by block randomization method, taking block size as 10 (5 in interventional \& conventional group each).

Intervention: In Experimental group the preoperative carbohydrate loading will be done.

The control group will undergo overnight fasting (minimum 6 hrs) preoperatively.

Monitoring and Assessment:

Variables to be measured:

Donor- Preoperative parameters: age, sex, BMI, LFTs, HbA1c, HOMA-IR, IL-6, CRP Operative parameters: Duration of surgery, blood loss, Postoperative serial measurements of the following from day one to discharge HOMA-IR, Lactate, IL-6, CRP, LFTs, PT-INR, Post operative nausea \& vomiting,

Day of discharge.

Timing of Sample Collection Group A Preoperative Baseline ( at 6 AM on day of surgery. Post-Operative:-6 hours after surgery \& then daily till discharge. Group B Preoperative Baseline ( at 6 AM on day of surgery. Post-Operative:-6 hours after surgery \& then daily till discharge. Adverse Effects: None

Statistical Analysis:

Data will be entered in excel worksheet and Statistical analyses will be performed with SPSS Statistics version 22 (IBM Corp., Armonk, NY). Statistical data will be represented as frequencies (%) where the continuous variables will be expressed as medians and interquartile range (IQRs). Continuous variables will be compared with the student t test and Mann-Whitney test as appropriate. Differences between proportions derived from categorical data will be compared with Chi-square or Fisher's exact test. Variables will be correlated with clinical outcomes. Repeated analysis of measures will be applied wherever applicable.

Stopping Rule- In case of significant adverse effects in the experimental arm. (c) EXPECTED OUTCOME:

  1. To establish that preoperative carbohydrate loading will decrease the post operative insulin resistance and enhances functional recovery after donor hepatectomy.
  2. To establish that preoperative carbohydrate loading reduces inflammatory stress response, incidence of post operative nausea \& vomiting and improves the surgical clinical outcomes.
02

Conditions studied

  • Healthy

Browse trials for

03

In context

Insulin Resistance

1,960 studies on the registry are indexed under Insulin Resistance; 305 are open to participants now.

This study's enrollment of 70 is above the median of 40 across 1,535 interventional studies indexed under Insulin Resistance.

Browse Insulin Resistance studies →

Lead sponsor

Institute of Liver and Biliary Sciences, India is the lead sponsor of 296 studies on the registry; 84 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • All consecutive live liver donors who undergo donor hepatectomy at ILBS

Exclusion criteria

Exclusion Criteria:

  1. Patients refusing to consent for inclusion in the study.
  2. Donor hepatectomy for ALF(acute liver failure) recipient
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
70 participants (actual)

Study arms

  • Other
    Overnight fasting

    overnight fasting(minimum 6 hrs) for control group.

    Other: overnight fasting

  • Experimental
    Maltodextrin

    Route: Oral Dose: * 400 ml at 10PM night before surgery(12.5g/100ml) * 200 ml in the morning at 6 AM (12.5g/100ml) on the day of surgery.

    Dietary Supplement: Maltodextrine

Interventions

  • Dietary supplementMaltodextrine

    400 ml at 10PM night before surgery(12.5g/100ml) 200 ml in the morning at 6 AM (12.5g/100ml) on the day of surgery.

  • Otherovernight fasting

    no intervention

06

What researchers measure

Primary outcomes

  1. To compare the insulin resistance by HOMA-IR(Homeostatic model assessment for insulin resistance) on postoperative day 2 between preoperative carbohydrate loading and conventional fasting group after donor hepatectomy.

    Time frame: Post operative day 2

Secondary outcomes

  1. To compare the functional recovery by total bilirubin on postoperative day 1

    Time frame: Post operative day 1

  2. To compare the functional recovery by PT/INR on postoperative day 1

    Time frame: Post operative day 1

  3. To compare the functional recovery by total bilirubin on postoperative day 3.

    Time frame: Post operative day 3

  4. To compare the functional recovery by PT/INR on postoperative day 3.

    Time frame: Post operative day 3

  5. To compare the functional recovery by total bilirubin on postoperative day 5.

    Time frame: Post operative day 5

  6. To compare the functional recovery by PT/INR on postoperative day 5.

    Time frame: Post operative day 5

  7. To compare the functional recovery by total bilirubin on postoperative day 7

    Time frame: Post operative day 7

  8. To compare the functional recovery by PT/INR on postoperative day 7

    Time frame: Post operative day 7

  9. To compare the functional recovery by total bilirubin on postoperative day 14.

    Time frame: Post operative day 14.

  10. To compare the functional recovery by PT/INR on postoperative day 14.

    Time frame: Post operative day 14.

  11. To compare the IL-6 levels after 48 hours of surgery.

    Time frame: 48 hours after surgery.

  12. To compare the C-reactive protein levels after 48 hours of surgery.

    Time frame: 48 hours after surgery.

  13. To compare the IL-6 levels on day 7 after surgery.

    Time frame: On day 7 after surgery.

  14. To compare the C-reactive protein levels on day 7 after surgery.

    Time frame: On day 7 after surgery.

  15. To compare the incidence of post operative nausea & vomiting till discharge

    Time frame: 1 week after surgery.

  16. To compare the length of hospital stay.

    Time frame: 2 weeks after surgery

07

Study locations

1 site
  • Institute of Liver and Biliary Sciences
    New Delhi, 110070, India
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05293444
Lead sponsor
Institute of Liver and Biliary Sciences, India
Responsible party
Sponsor
First posted
Mar 24, 2022
Start date
Feb 1, 2022
Primary completion
Nov 30, 2022
Completion
Nov 30, 2022
Last update
Dec 5, 2023

Study contacts

Viniyendra Pamecha, MS, FRCS(UK)
study director · Institute of Liver and Biliary Sciences, New Delhi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion